09/30/2020
The American Psychiatric Association recently released Covid-19 Guidance emphasizing that continued and uninterrupted administration of long-acting injectable medication for mentally ill patients with high-risk illnesses is a necessary procedure and that the risks of changing medications at this time are heightened at this time due to the pandemic. The document emphasized that the withdrawal of these treatments could lead to harmful destabilization of seriously mentally ill patients and dramatically increase their risk of physical and psychiatric decompensation.
“In the context of a pandemic, these risks are significantly elevated due to reduced natural supports, reduced access to outpatient treatment including pharmacy services and the risk of exposure to the coronavirus with increased contacts with the community, healthcare, and criminal justice system. For many with severe and chronic mental illness, the use of these long-acting formulations can reduce personal suffering and distress, especially in a pandemic; for others, it has also reduced disorganized or impulsive behaviors that put them at risk of physical injury, aggression, utilization of emergency rooms or incarceration. LAI (Long-Acting Injectable) can also help ensure an adequate level of functioning and cognitive processing which would enable these patients to practice social distancing in a pandemic,” According to the document. (See Use of Long-Acting Injectables as a Clinically Necessary Treatment, APA Committee on the Psychiatric Dimensions of Disaster and COVIDæ19, American Psychiatric Association).